期刊
CHEMMEDCHEM
卷 5, 期 10, 页码 1760-1769出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.201000252
关键词
cancer; dihydropyrimidines; kinesin inhibitors; molecular docking; multicomponent reactions
资金
- Cancer Research UK
Dihydropyrimidine-based compounds belong to the first discovered inhibitors of the human mitotic kinesin Eg5. Although they are used by many research groups as model compounds for chemical genetics, considerably less emphasis has been placed on the improvement of this type of inhibitor, with the exception of two recent studies. Dihydropyrimidines can be divided into class I (analogues that bind in the S configuration) and class II type inhibitors, which bind in the R configuration. Herein we report the synthesis and optimization of novel class II type dihydropyrimidines using a combination of in vitro and docking techniques.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据